<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744613</url>
  </required_header>
  <id_info>
    <org_study_id>822</org_study_id>
    <nct_id>NCT01744613</nct_id>
  </id_info>
  <brief_title>High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures</brief_title>
  <acronym>PRECLOP</acronym>
  <official_title>Clinical Impact of High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures. The PRECLOP Study (Platelet REsponsiveness to CLOpidogrel Treatment After Peripheral Angioplasty or Stenting)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antiplatelet therapy with clopidogrel is recommended following peripheral endovascular
      procedures. The clinical significance of an inadequate response to clopidogrel following
      percutaneous coronary interventions has been recently recognized.This study was designed to
      investigate platelet responsiveness to Clopidogrel following endovascular therapy of
      peripheral arterial disease using the VerifyNow P2Y12 point-of-care testing and to determine
      the optimal P2Y12 reactive unites (PRU) cut-off value of platelet inhibition influencing
      outcomes of infrainguinal angioplasty or stenting in patients receiving clopidogrel
      antiplatelet therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Major event-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>12 months freedom from all causes of death, stroke, index limb amputation, non pre-scheduled minor amputation, index limb bypass surgery and target vessel recanalization (TVR)stratified according to PRU values distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal P2Y12 reactive unites (PRU) cut-off value of platelet inhibition</measure>
    <time_frame>12 months</time_frame>
    <description>Optimal P2Y12 reactive unites (PRU) cut-off value of platelet inhibition measured with VerifyNow P2Y12 assay point-of-care testing, influencing the 12 months primary outcome of major event-free survival estimated by ROC analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and negative predictive value of PRU testing</measure>
    <time_frame>12 months</time_frame>
    <description>Positive and negative predictive value of PRU measurement with regard to the primary outcome of major event-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding rate</measure>
    <time_frame>12 months</time_frame>
    <description>12-months bleeding rate including intracranial hemorrhage and puncture related pseudoaneurysm stratified according to PRU values</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Influence of PRU Values on Primary Outcome</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Will include patients with PRU values above the optimal cut-off value determined by ROC analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Will include patients with PRU values below the optimal cut-off value determined by ROC analysis.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patient sampling of all patients undergoing pre-scheduled infrainguinal
        angioplasty or stenting due to symptomatic arterial disease in our Department from January
        2010, treated with clopidogrel 75 mg daily.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from Rutherford 3-6 stage of peripheral arterial disease scheduled
             to undergo femoropopliteal or and infrapopliteal angioplasty or stenting.

          -  Patients receiving Clopidogrel per os 75 mg daily at least 1 month prior and 1 year
             after the procedure.

        Exclusion Criteria:

          -  Acute limb ischemia

          -  Coagulation disorders

          -  Known allergy to clopidogrel

          -  Failure to comply with the antiplatelet treatment protocol

          -  Aortoiliac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitrios Siablis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dimitrios Karnabatidis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stavros Spiliopoulos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georgios Pastromas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Konstantinos Katsanos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Patras</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Patras University Hospital</name>
      <address>
        <city>Rion</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>January 11, 2013</last_update_submitted>
  <last_update_submitted_qc>January 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>SIABLIS DIMITRIOS</investigator_full_name>
    <investigator_title>Dimitrios Siablis, Professor of Radiology</investigator_title>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>platelet inhibition</keyword>
  <keyword>antiplatelet therapy</keyword>
  <keyword>peripheral arterial disease</keyword>
  <keyword>endovascular treatment</keyword>
  <keyword>angioplasty</keyword>
  <keyword>stenting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

